202 related articles for article (PubMed ID: 16884321)
1. Comparison of equivalent doses of fentanyl buccal tablets and arteriovenous differences in fentanyl pharmacokinetics.
Darwish M; Kirby M; Robertson P; Hellriegel E; Jiang JG
Clin Pharmacokinet; 2006; 45(8):843-50. PubMed ID: 16884321
[TBL] [Abstract][Full Text] [Related]
2. Bioequivalence following buccal and sublingual placement of fentanyl buccal tablet 400 microg in healthy subjects.
Darwish M; Kirby M; Jiang JG; Tracewell W; Robertson P
Clin Drug Investig; 2008; 28(1):1-7. PubMed ID: 18081355
[TBL] [Abstract][Full Text] [Related]
3. Dose proportionality of fentanyl buccal tablet in doses ranging from 600 to 1300 microg in healthy adult subjects: a randomized, open-label, four-period, crossover, single-centre study.
Darwish M; Kirby M; Robertson P; Tracewell W; Xie F
Clin Drug Investig; 2010; 30(6):365-73. PubMed ID: 20441245
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic properties of fentanyl effervescent buccal tablets: a phase I, open-label, crossover study of single-dose 100, 200, 400, and 800 microg in healthy adult volunteers.
Darwish M; Kirby M; Robertson P; Tracewell W; Jiang JG
Clin Ther; 2006 May; 28(5):707-14. PubMed ID: 16861092
[TBL] [Abstract][Full Text] [Related]
5. Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers.
Darwish M; Tempero K; Kirby M; Thompson J
Clin Ther; 2006 May; 28(5):715-24. PubMed ID: 16861093
[TBL] [Abstract][Full Text] [Related]
6. Absorption of fentanyl from fentanyl buccal tablet in cancer patients with or without oral mucositis: a pilot study.
Darwish M; Kirby M; Robertson P; Tracewell W; Jiang JG
Clin Drug Investig; 2007; 27(9):605-11. PubMed ID: 17705569
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and dose proportionality of fentanyl effervescent buccal tablets in healthy volunteers.
Darwish M; Tempero K; Kirby M; Thompson J
Clin Pharmacokinet; 2005; 44(12):1279-86. PubMed ID: 16372825
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of fentanyl buccal tablet: a pooled analysis and review.
Darwish M; Xie F
Pain Pract; 2012 Apr; 12(4):307-14. PubMed ID: 21831253
[TBL] [Abstract][Full Text] [Related]
9. Effect of buccal dwell time on the pharmacokinetic profile of fentanyl buccal tablet.
Darwish M; Kirby M; Jiang JG
Expert Opin Pharmacother; 2007 Sep; 8(13):2011-6. PubMed ID: 17714055
[TBL] [Abstract][Full Text] [Related]
10. Fentanyl buccal tablet: in breakthrough pain in opioid-tolerant patients with cancer.
Blick SK; Wagstaff AJ
Drugs; 2006; 66(18):2387-93; discussion 2394-5. PubMed ID: 17181383
[TBL] [Abstract][Full Text] [Related]
11. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study.
Simpson DM; Messina J; Xie F; Hale M
Clin Ther; 2007 Apr; 29(4):588-601. PubMed ID: 17617282
[TBL] [Abstract][Full Text] [Related]
12. Absolute and relative bioavailability of fentanyl buccal tablet and oral transmucosal fentanyl citrate.
Darwish M; Kirby M; Robertson P; Tracewell W; Jiang JG
J Clin Pharmacol; 2007 Mar; 47(3):343-50. PubMed ID: 17322146
[TBL] [Abstract][Full Text] [Related]
13. Fentanyl buccal tablet.
Messina J; Darwish M; Fine PG
Drugs Today (Barc); 2008 Jan; 44(1):41-54. PubMed ID: 18301803
[TBL] [Abstract][Full Text] [Related]
14. Single-dose and steady-state pharmacokinetics of fentanyl buccal tablet in healthy volunteers.
Darwish M; Kirby M; Robertson P; Hellriegel E; Jiang JG
J Clin Pharmacol; 2007 Jan; 47(1):56-63. PubMed ID: 17192502
[TBL] [Abstract][Full Text] [Related]
15. Dose Proportionality and Pharmacokinetics of Fentanyl Buccal Soluble Film in Healthy Subjects : A Phase I, Open-Label, Three-Period, Crossover Study.
Finn AL; Vasisht N; Stark JG; Gever LN; Tagarro I
Clin Drug Investig; 2012 Jan; 32(1):63-71. PubMed ID: 27933600
[TBL] [Abstract][Full Text] [Related]
16. Dose proportionality and pharmacokinetics of fentanyl buccal soluble film in healthy subjects: a phase I, open-label, three-period, crossover study.
Finn AL; Vasisht N; Stark JG; Gever LN; Tagarro I
Clin Drug Investig; 2012 Jan; 32(1):63-71. PubMed ID: 22128878
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics, safety, and tolerability of ascending doses of sublingual fentanyl, with and without naltrexone, in Japanese subjects.
Lister N; Warrington S; Boyce M; Eriksson C; Tamaoka M; Kilborn J
J Clin Pharmacol; 2011 Aug; 51(8):1195-204. PubMed ID: 21209242
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the single- and multiple-dose pharmacokinetics of fentanyl buccal soluble film in normal healthy volunteers.
Vasisht N; Gever LN; Tagarro I; Finn AL
J Clin Pharmacol; 2010 Jul; 50(7):785-91. PubMed ID: 20150521
[TBL] [Abstract][Full Text] [Related]
19. Relative Bioavailability of Fentanyl Following Various Dosing Regimens of Fentanyl Buccal Tablet in Healthy Japanese Volunteers.
Darwish M; Tempero K; Jiang JG; Simonson PG
Arch Drug Inf; 2008 Sep; 1(2):56-62. PubMed ID: 19915709
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and tolerability of different doses of fentanyl following sublingual administration of a rapidly dissolving tablet to cancer patients: a new approach to treatment of incident pain.
Lennernäs B; Hedner T; Holmberg M; Bredenberg S; Nyström C; Lennernäs H
Br J Clin Pharmacol; 2005 Feb; 59(2):249-53. PubMed ID: 15676050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
